Liu, Mingyue
Wang, Xu
Du, Xuexiang
Zhang, Yan
Ai, Chunxia
Hu-Lieskovan, Siwen
Li, Tianhong
Devenport, Martin
Liu, Yang http://orcid.org/0000-0002-9442-700X
Zheng, Pan
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01AI154722, R01AI154722, R01AI154722, R01CA227671, R01AI154722)
OncoImmune, Inc
Melanoma Research Alliance (559400, 559400, 559400)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 13 February 2022
Revised: 3 May 2022
Accepted: 15 May 2022
First Online: 15 July 2022
Competing interests
: P.Z. and Y.L. are cofounders of and have significant equity interest in OncoC4, Inc. Other authors declare no competing interests.
: All studies involving mice have been approved by the Institutional Animal Care and Use Committee of the Children’s National Medical Center or the Institute of Human Virology at the University of Maryland Baltimore School of Medicine.